PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $27.88 per share as of 2019-12-31, per its 10-K filed 2020-03-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2020-03-03
- 2019-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $27.88.
- 2018-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $32.47.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2019-12-31 | $27.88 10-K · filed 2020-03-03 |
| 2018-12-31 | $32.47 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |